Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KLK1 | P06870 | 1/20 | 0.31 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23508247 | 0.90 | GSK3B (0.33) | CDK2GSK3B | |
| SCHEMBL23508346 | 0.90 | PTGS2 (0.34) | CDK2GSK3BKLK1KLK5 | |
| SCHEMBL23497790 | 0.88 | KLK1 (0.36) | CDK2GSK3BSMN1; SMN2KLK1KLK5 | |
| SCHEMBL25140202 | 0.86 | SMN1; SMN2 (0.31) | SMN1; SMN2GAAKLK1KLK5 | |
| SCHEMBL23508299 | 0.83 | GSK3B (0.36) | CDK2GSK3BSMN1; SMN2GAAKLK1 | |
| SCHEMBL23508316 | 0.82 | CACNA1H (0.35) | CDK2GSK3B | |
| SCHEMBL23508393 | 0.79 | CSNK1E (0.41) | GSK3B | |
| SCHEMBL23508574 | 0.79 | CSNK1E (0.42) | CDK2GSK3BNPC1RAB9A | |
| SCHEMBL23508567 | 0.79 | CDK12 (0.44) | GSK3B | |
| SCHEMBL23508413 | 0.78 | CTNNB1 (0.32) | CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| EP-4073072-A1 | PYRAZOLOTRIAZINES | Bayer Aktiengesellschaft (DE) | 2022-10-19 | — | — | EP | disclosed |
| CN-115023427-A | Pyrazolotriazines | 拜耳公司 | 2022-09-06 | — | — | CN | disclosed |
| WO-2021116178-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BRCA1, TPX2, CCND2 | CDK2 43/4885GSK3B 3545/4885SMN1; SMN2 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.